Yiğit Kaya, S. Et Al. 2024. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience. Leukemia Research , vol.140 .

Yiğit Kaya, S., MUTLU, Y. G., MALKAN, Ü. Y., MEHTAP, Ö., Keklik Karadağ, F., Korkmaz, G., ... ELVERDİ, T.(2024). Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience. Leukemia Research , vol.140.

Yiğit Kaya, Süreyya Et Al. "Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience," Leukemia Research , vol.140, 2024

Yiğit Kaya, Süreyya Y. Et Al. "Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience." Leukemia Research , vol.140, 2024

Yiğit Kaya, S. Et Al. (2024) . "Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience." Leukemia Research , vol.140.

@article{article, author={Süreyya Yiğit Kaya Et Al. }, title={Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience}, journal={Leukemia Research}, year=2024}